Latigo Biotherapeutics: Guggenheim's buy recommendation with over 100% upside potential draws attention to NaV1.8 inhibitors

Latigo Biotherapeutics (LTGO) focuses on non-opioid analgesics for acute and chronic pain. On September 1, Guggenheim analyst Yatin Suneja issued a "Buy" recommendation for the stock (target price: $50). The company's pipeline candidates target NaV1.8 channels to eliminate the risk of addiction associated with treatment. Business Model and Regulatory Growth Trends Latigo Biotherapeutics (LTGO) operates as a clinical-stage biopharmaceutical company dedicated to researching non-opioid pain medications. Its business model centers on modulating...